Neuland Laboratories Q2 Results: Earnings call audio uploaded for investors

1 min read Updated on 06 Aug 2026, 12:44 AM

Reviewed by

Shriram SScanX News Team

AI Summary

Neuland Laboratories Limited disclosed the audio link for its Q2FY27 earnings call held on August 5, 2026. The filing, compliant with SEBI Regulation 30, allows investors to review management's discussion on financial results for the quarter ended June 30, 2026.

*this image is generated using AI for illustrative purposes only.

Neuland Laboratories Limited has released the audio recording of its earnings call for the quarter ended June 30, 2026. The conference call took place on August 5, 2026, providing investors and analysts with direct access to management’s commentary on the company’s financial performance and operational updates for the period.

The disclosure was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Neuland Laboratories submitted the weblink to the audio recording to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Ltd (NSE) on August 5, 2026.

Accessing the Recording

Investors can access the earnings call recording through the company’s official investor relations portal. The link directs users to the dedicated section for investor meeting recordings on the Neuland Laboratories website.

Detail	Information
Event	Earnings Call
Period Covered	Quarter ended June 30, 2026
Date of Call	August 5, 2026
Disclosure Date	August 5, 2026
Regulatory Basis	SEBI LODR Regulation 30
Access Link	Investor Call Recordings

Regulatory Compliance

The filing was signed by Sarada Bhamidipati, Company Secretary at Neuland Laboratories Limited. The submission ensures transparency and equal access to information for all stakeholders, adhering to the mandatory disclosure norms set by Indian securities regulators. The notice was addressed to the respective exchanges at their Mumbai offices: Phiroze Jeejeebhoy Towers for BSE and Exchange Plaza for NSE.

Historical Stock Returns for Neuland Laboratories

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+3.54%	+5.75%	+5.28%	+47.47%	+52.53%	+1,026.98%

How will the Q2 2026 financial performance influence Neuland Laboratories' dividend policy or capital allocation strategy for the remainder of FY2027?

What specific operational initiatives did management highlight during the call to address potential supply chain bottlenecks or raw material cost inflation?

Are there any updates on the regulatory status of Neuland's key generic drug approvals in major markets like the US or Europe that could impact future revenue streams?

Read Next Article

Neuland Laboratories Q1FY27: Net profit surges 975% YoY to ₹147.4 crore

2 min read Updated on 05 Aug 2026, 05:18 PM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

AI Summary

Neuland Laboratories posted a 975% YoY surge in net profit to ₹147.4 crore for Q1FY27, supported by robust revenue growth of 116.3% to ₹650.1 crore. The company saw significant margin expansion and improved working capital efficiency, despite a sequential decline in quarterly figures.

*this image is generated using AI for illustrative purposes only.

Neuland Laboratories Limited reported a net profit of ₹147.4 crore for the quarter ended June 30, 2026, marking a 975% surge from ₹13.7 crore in Q1FY26. The Hyderabad-based pharmaceutical manufacturer saw total income rise 116.3% year-on-year (YoY) to ₹650.1 crore, driven by robust performance across its Custom Manufacturing Services (CMS) and Generic Drug Sales (GDS) segments. This significant turnaround underscores the company’s operational leverage as it scales production capabilities, with EBITDA climbing 448.2% to ₹231.1 crore.

The filing, submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, highlights a sharp expansion in profitability metrics. Profit before tax (PBT) increased 1,036.7% to ₹197.5 crore, demonstrating effective cost management alongside revenue growth. Earnings per share (EPS) stood at ₹114.9, up from ₹10.7 in Q1FY26. While quarterly figures showed a sequential decline due to seasonal variations, the year-on-year comparison reveals substantial growth in underlying business health.

Financial Performance Overview

Particulars	Q1FY27	Q1FY26	YoY (%)	Q4FY26	QoQ (%)
Total Income	650.1	300.6	116.3%	788.7	-17.6%
EBITDA	231.1	42.1	448.2%	319.4	-27.6%
EBITDA Margin	35.5%	14.0%	2150 bps	40.5%	-500 bps
Profit Before Tax	197.5	17.4	1036.7%	287.0	-31.2%
PBT Margin	30.4%	5.8%	2460 bps	36.4%	-601 bps
Profit After Tax	147.4	13.7	975.0%	212.5	-30.6%
PAT Margin	22.7%	4.6%	1811 bps	26.9%	-423 bps
EPS (₹)	114.9	10.7	975.0%	165.6	-30.6%

Business Segment Highlights

The CMS segment saw revenues driven by commercial molecules, with growth in new project orders expected to be delivered over this and next financial years. There is notable traction from innovators with peptide molecules in the pipeline. In the GDS segment, Ezetimibe and Mirtazapine were key molecules in the Prime segment, with Ezetimibe likely to drive future growth. The Specialty business was driven by Aripiprazole Sterile, Donepezil, and Apixaban.

Balance Sheet and Working Capital

Working capital days of sale improved significantly to 84 days in Q1FY27, down from 137 days in Q4FY26, mainly due to a decrease in receivables. Capex outflow stood at ₹122 crore in Q1FY27. Net debt increased to ₹308.5 crore as of June 30, 2026, compared to ₹164.7 crore in Q1FY26 and ₹156.8 crore in Q4FY26. Shareholder funds rose to ₹2,013.2 crore from ₹1,865.9 crore in March 2026.

What the Numbers Show

The divergence between revenue growth and profit expansion is notable. While total income grew 116.3% YoY, net profit surged 975%. This disproportionate rise suggests significant operating leverage, where fixed costs are spread over a larger revenue base, boosting margins. The EBITDA margin expansion of 2,150 basis points further confirms improved operational efficiency. However, the QoQ decline in both income and profit indicates potential seasonality or one-off factors in the previous quarter that inflated those numbers, making the YoY comparison more reflective of underlying business health. Management notes that investment intensity will likely increase based on available opportunities to build customer confidence.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE794A01010/d9d252d9-3fba-4f1f-bc61-e3a4d9ae752a.pdf

Historical Stock Returns for Neuland Laboratories

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+3.54%	+5.75%	+5.28%	+47.47%	+52.53%	+1,026.98%

How will the increased capex outflow of ₹122 crore and rising net debt to ₹308.5 crore impact Neuland's debt-to-equity ratio and interest coverage in the coming quarters?

What is the expected timeline for revenue recognition from the new peptide molecule projects in the CMS segment, and how significant will they be to overall growth?

Given the sequential decline in QoQ metrics, what specific seasonal factors or one-off events contributed to the inflated Q4FY26 numbers, and how might this affect Q2FY27 guidance?